Purpose: Poorly differentiated
thyroid cancer and
anaplastic thyroid cancer (ATC) are rare yet lethal
malignancies with limited treatment options. Many malignant
tumors, including
papillary thyroid cancer (PTC) and ATC, are associated with increased expression of
ICAM-1, providing a rationale for utilizing ICAM-1-targeting agents for the treatment of aggressive
cancer. We developed a third-generation
chimeric antigen receptor (CAR) targeting
ICAM-1 to leverage adoptive T-cell
therapy as a new treatment modality.Experimental Design:
ICAM-1 CAR T cells were applied to multiple malignant and nonmalignant target cells to investigate specific target cell death and "off-
tumor" toxicity in vitroIn vivo therapeutic efficacy of
ICAM-1 CAR T cells was examined in ATC mouse models established from a cell line and patient-derived
tumors that rapidly develop systemic
metastases.Results:
ICAM-1 CAR T cells demonstrated robust and specific killing of PTC and ATC cell lines in vitro Interestingly, although certain ATC cell lines showed heterogeneous levels of
ICAM-1 expression, addition of cytotoxic CAR T cells induced increased
ICAM-1 expression such that all cell lines became targetable. In mice with systemic ATC, a single administration of
ICAM-1 CAR T cells mediated profound
tumor killing that resulted in long-term remission and significantly improved survival. Patient-derived ATC cells overexpressed
ICAM-1 and were largely eliminated by autologous
ICAM-1 CAR T cells in vitro and in animal models.Conclusions: Our findings are the first demonstration of CAR T
therapy against both a metastatic,
thyroid cancer cell line and advanced ATC patient-derived
tumors that exhibit dramatic therapeutic efficacy and survival benefit in animal studies. Clin
Cancer Res; 23(24); 7569-83. ©2017 AACR.